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Objective. Comorbidities between psychiatric diseases and consumption of traditional substances of abuse (alcohol, cannabis,
opioids, and cocaine) are common. Nevertheless, there is no data regarding the use of novel psychoactive substances (NPS)
in the psychiatric population. The purpose of this multicentre survey is to investigate the consumption of a wide variety of
psychoactive substances in a young psychiatric sample and in a paired sample of healthy subjects. Methods. A questionnaire has
been administered, in different Italian cities, to 206 psychiatric patients aged 18 to 26 years and to a sample of 2615 healthy subjects
matched for sex, gender, and living status. Results. Alcohol consumption was more frequent in the healthy young population
compared to age-matched subjects suffering from mental illness (79.5% versus 70.7%; 푃 < 0.003). Conversely, cocaine and NPS
use was significantly more common in the psychiatric population (cocaine 8.7% versus 4.6%; 푃 = 0.002) (NPS 9.8% versus 3%;푃 < 0.001). Conclusions. The use of novel psychoactive substances in a young psychiatric population appears to be a frequent
phenomenon, probably still underestimated. Therefore, careful and constant monitoring and accurate evaluations of possible
clinical effects related to their use are necessary.
1. Introduction
It is well known that mental disorders are accompanied by
multiple comorbidities, but substance misuse is particularly
common [1]. Many clinicians feel that substance misuse may
be explained in some cases as a form of self-medication
to improve psychopathology (depression, anhedonia, and
negative symptoms) or to ameliorate the side effects of
psychopharmacological treatment. Indeed, the cooccurrence
between mental disorders and psychoactive substances mis-
use often leads to a more pernicious and difficult to treat
course of illness, in terms of possible earlier age of onset,
frequency and length of episodes, and diminished treatment
compliance [2, 3]. Moreover, there is substantial evidence
that substance misuse is a major risk factor for violence and
aggression in patients with major mental disorders [4]. To
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get an idea of the problem dimension as a health issue, in
2010mental and substance use disorders accounted for 183.9
million disability-adjusted life years (DALYs) or 7.4% of all
DALYs worldwide. Thus, considered together, mental and
substance use disorders were the leading cause of years lived
with disability (YLDs) worldwide [5]. The long-term con-
sequences of increased reactivity (sensitisation) to episodes
and substances misuse and their cross-sensitisation to each
other may have a number of important implications for
clinical therapeutics [2, 6]. The potential cross-sensitisation
among stressors, episodes, and substances misuse raises the
spectre of an adverse positive feedback mechanism in each
domain of illness vulnerability, with recurrences of each not
only increasing responsivity to itself, but also increasing
responsivity to the others [2].
Recently, beyond “classic” substances of abuse, it seems
that novel (new) psychoactive substances (NPS) are deter-
mining a further sanitary issue of growing importance, espe-
cially in relation to the fast-moving and potentially unlimited
nature of their online market [7].The term “novel psychoac-
tive substances” (NPS) has been legally defined by European
Union as a new narcotic or psychotropic drug, in pure
form or in a preparation, that is not scheduled under the
Single Convention on Narcotic Drugs of 1961 or the Conven-
tion on Psychotropic Substances of 1971, but may pose a pub-
lic health threat comparable to that posed by substances listed
in those conventions (Council of the European Union deci-
sion 2005/387/JHA) [8]. NPS are often almost unknown to
health professionals,mainly due to the lack of evidence-based
sources of information [9]. Since 1997, more than 200 novel
psychoactive compounds have been reported; out of these, 41
were reported in 2010, 60 in 2011, and 57 in 2012 [7]. These
substances are most often synthesized in underground lab-
oratories, simply modifying the molecular structure of con-
trolled drugs, hence raising further concerns in terms of the
presence of contaminating agents [8]. The World Wide Web
has emerged as a primary source of information about drugs
in general andNPS in particular. Drug users can obtain infor-
mation through online forums, chat rooms, and blogs and
find out about new products. They can also communicate
with other users about their experiences, the effects of the
substances, and the recommended sources and routes of
delivery.This may be an issue of concern if one considers that
an estimated 61% of young European people aged between 15
and 24 years typically quote the Internet as a potential source
of information on drugs [10]. The number of online shops
offering to supply with NPS customers residing in European
countries increased from 170 in January 2010 to 314 in January
2011 and 693 in January 2012 [7].The possibility of purchasing
NPS fromweb sites makes these drugs very easily available to
vulnerable individuals, including children and adolescents.
Vulnerable consumers are targeted by aggressive marketing
strategies (attractive names, colourful packaging, and free
samples to test); NPS appear to be mostly unregulated, and
this may facilitate their popularity as well as the users’ per-
ception of risks associated with consumption. The idea that
legality can equate with safety still remains well grounded
amongst some recreational users [9].
Thus, the focus on novel psychoactive substances, pecu-
liarly in youths, has become a diffuse topic of discussion in
scientific literature, underlining a growing interest for this
widespread phenomenon. However, still few epidemiologi-
cal data about NPS diffusion exists. Recent data by Euro-
pean Monitoring Centre on Drugs and Drug Addiction
(EMCDDA) highlights that small percentages of tested
youths have experienced NPS (around 5%), most of them
obtaining drugs from friends or at parties, rather than online
[11]. A UK-based research found out that almost one-third of
a sample of students (446) had tried NPS at least once in their
life. A Polish epidemiological study on 14511 secondary school
pupils and university students has registered NPS use rate of
4.49% and 1.83%, respectively [12]. The psychoactive sub-
stances abuse issue has been recently emphasized by resea-
rchers from all over the world: Madruga et al. have gathered
information on a sample of 761 Brazilians aged from 14 to
19 years old; more than half of interviewed adolescents are
regular alcohol users and one out of ten is an abuser and/or
dependent, while nearly 3% has used an illicit substance in
the twelve months before questionnaire administration [13].
Famuyiwa and colleagues supply epidemiologic data on 4286
school pupils (mean age 15.2 years) from Lagos, Nigeria,
finding that 61.8% of respondents have used one or more
psychoactive substances in their lifetime [14]. Currie reports
results on Salvia divinorum consumption from Canada’s
Youth Smoking Survey (sample of 42179 Canadian adoles-
cents aged 12–17 years), evidencing that 6.2% of the subjects
has used the substance at least once in their life [15]. Kelly et al.
have performed a field-based survey of 1740 patrons at
nightlife venues in New York City. Within the sample, 8.2%
reported use of synthetic cannabinoids and 1.1% reported use
of mephedrone; the findings suggest that the use of synthetic
cannabinoids and mephedrone among US nightlife scenes
may remain relatively low in comparison with European
nightlife scenes [16]. A recent study by Bruno et al. among 693
regular ecstasy users (REU) in Australia has evidenced that
more than one quarter (28%) of REU have used a new psy-
choactive substance in the past six months, most commonly
from the stimulant class (20%, typically mephedrone 17%)
rather than from the psychedelic class (13%) [17]. These
behaviours and patterns of use are encouraged by the
increasing phenomenon of binge drinking, widely diffused in
Europe and North America [18–20].
To the best of our knowledge, no current data exist about
the use of NPS among psychiatric patients. This is the first
study aiming to assess both the presence and the nature of
NPS misuse in a population of Italian young adults in com-
parison with a psychiatry patient sample.
2. Materials and Methods
A questionnaire has been administered to a sample of 2615
healthy subjects, aged between 18 and 26 years. The instru-
ment has been designed by comparing different theories and
points of view about abuse and addiction.The data were col-
lected between September 2013 and January 2014; the ques-
tionnaire was self-administered in an anonymous way by our
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team of psychologists and psychiatrists, with the support of a
peer-working group. We investigated socioeconomic charac-
teristics (age, gender, residence, job status, level of education,
and living status), alcohol use, and substance use (tobacco,
caffeine, cannabis, and cocaine) with a peculiar focus
on Novel Psychoactive Substances (NPS).The NPS we inves-
tigated are as follows: synthetic cannabinoids (spices),
mephedrone (bath salts), methamphetamine (ice-shaboo-
crystal meth), Ayahuasca, phenethylamines (Nbome-Fly-
Solaris), Salvia divinorum, Kratom, gamma hydroxybutyric
acid (GHB), methoxetamine (Special M), and desomorphine
(krokodil).
The selected sample resided in different Italian cities,
located in the north, centre, and south of the country, to
ensure the inclusion of youths from diverse social and
provenance contexts.
The same survey has been administered to a sample of 206
psychiatric patients, with DSM-5 fixed diagnoses at the time
of test, excluding those with a substance use disorder. The
patients were recruited in eight departments of mental health
in various Italian cities, located in the north, centre, and south
of the country to ensure a comparable sample. Healthy
subjects were selected homogeneously by age, gender, and
housing condition, following as a randomizing procedure the
Snowball sampling [21]. The psychiatric subjects sample
was composed of all the new inpatients admitted in the 8
recruiting centres in the period between December 2013 and
March 2013.
Data collection was carried out in an anonymous and
confidential way; all participants received a detailed explana-
tion of the design of the study and awritten informed consent
was systematically obtained from every subject, according to
the Declaration of Helsinki.
Baseline data were analysed using descriptive statistics,
including means and standard deviations and frequencies
and percentages.The chi-square (휒2) test, Fisher’s exact test,
and nonparametric Wilcoxon-Mann-Whitney test were used
for comparison of qualitative data. Quantitative variables
were summarized by means and medians and compared
using the Student’s 푡-test. Factors with a 푃 value lower than
0.25 were included in the multivariate analysis and 푃 value
lower than 0.05was considered to be significant. SPSS version
14.0 was used for all analyses.
3. Results
The sample of 2615 healthy subjects consisted of 44.6% of
males and of 55.4% of females, with a mean age of 22.01 ± 2.6
years.The sociodemographic data indicated that themajority
of respondents had attended high school (66.6%), was living
with parents (67.4%), and was a student (59%).
On the other hand, the sample of 206 psychiatric patients
(20.9% diagnosed with schizophrenia or other psychotic
disorders, 15.5%with depressive disorders, 13.1%with bipolar
disorder, 27.2% with anxiety disorders, 17% with personality
disorders, and 6.3% with Obsessive Compulsive Disorder)
was composed of 45.6% males and 54.4% of females, with a
mean age of 22.4 ± 2.7 years. 63.8% of patients had attended
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Figure 1: Psychoactive substances.
high school, 75.5% was living with parents, and 37.4% was a
student at the time of testing (Table 1).
Habitual consumption of alcoholic beverages was signif-
icantly more common in healthy subjects than in patients
(79.5% versus 70.7%; 푃 < 0.003), as well as Binge Drinking
behaviours (59.7% versus 47.6%; 푃 < 0.001).
With regard to the association of alcohol consumption
with use of other substances (37.8% in healthy subjects
and 45.3% in patients), there was no statistically significant
difference between two groups.
The data on the consumption of drugs indicated that the
difference in cannabis use between the two groups (25.6% in
healthy subjects and 29.3% in patients) was not statistically
significant, while both cocaine (8.7% versus 4.6%; 푃 = 0.002)
and NPS use (9.8% versus 3%; 푃 < 0.001) prevailed among
patients.
The differences in coffee consumption (80.4% in healthy
subjects and 82.4% in patients) and cigarettes smoking
(46.7% in healthy subjects and 52.7% in patients) were not
statistically significant between the two groups (Figure 1).
Regarding the consumption of substances in the sample of
psychiatric patients, those with a diagnosis of schizophrenia
and other psychotic disorders used to consume alcohol in
65.6% of cases, had binge drinking behaviours in 51.2% of
cases, used cannabinoids in 41.9%of cases, consumed cocaine
in 9.3% of cases, and used NPS in 9.3% of cases; those
diagnosed with depressive disorders consumed alcohol in
75% of cases, with a binge prevalence of 53.1%; cannabinoids
were used in 21.9% of cases, cocaine in 6.3%, and NPS in
15.6%. Patient with a diagnosis of bipolar disorder consumed
alcohol in 88.9%of cases, with concomitant binge drinking in
70.4% of the sample; use of cannabinoids was evidenced in
48.1% of cases, cocaine in 18.5%, and NPS in 14.8%. Those
diagnosed with anxiety disorders consumed alcohol in 66.1%
of cases, with a prevalence of binge behaviours of 41.1%; use
of cannabinoids was reported in 14.3% of cases, cocaine in
5.4%, and NPS in 8.9%. Patients diagnosed with personality
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Table 1: Sociodemographic characteristics.
Variable Psychiatric patients (%) Healthy subjects (%)
Age 21.4 ± 2.7 years 22.01 ± 2.6 years
Gender Male: 45.6% Male: 44.6%
Female: 56.4% Female: 55.4%
Level of educational
Primary degree: 1.5% Primary degree: 0.2%
Middle school: 21.7% Middle school: 8%
High school: 63.1% High school: 66.6%
University: 13.8% University: 25.1%
Job status
Student: 37.4% Student: 59%
Student/worker: 8.7% Student/worker: 10.8%
Worker: 22.3% Worker: 19.7%
Unemployed: 31.6% Unemployed: 10.5%
Living status
Parents: 75.5% Parents: 67.4%
Friends: 9.3% Friends: 20.6%
Alone: 10.3% Alone: 8.1%
Partner: 4.9% Partner: 4%
Psychiatric diagnosis (DSM-5)
Psychotic Disorders: 20.9% —
Depressive disorders: 15.5% —
Bipolar disorder: 13.1%, —
Anxiety disorders: 27.2% —
Personality disorders: 17% —
DOC: 6.3% —
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Figure 2: Psychoactive substances use in psychiatric patients.
disorder drank alcohol in 76.5% of cases, had binge drinking
behaviours in 42.9%of cases, and used cannabinoids in 38.2%
of cases, cocaine in 11.4%, and NPS in 5.7%.Those diagnosed
with DOC consumed alcohol in 61.5% of cases, with a binge
prevalence of 15.4%; they smoked cannabinoids in 7.7% of
cases but did not use cocaine or NPS (Figure 2).
More specifically, with regard to the use of NPS, our data
revealed that among healthy subjects 1.6% had experimented
with methamphetamine, 1.1%with Salvia divinorum, 1%with
synthetic cannabinoids, 0.6% with phenethylamines, 0.3%
with mephedrone, 0.3% with GHB, 0.2% with Ayahuasca,
0.2% with methoxetamine, 0.2% with desomorphine, and
0.1% with kratom.
In the psychiatric patients’ sample, we evidenced that
5.8% used Synthetic Cannabinoids, 3.4%methamphetamine,
1.9% GHB, 1% Salvia divinorum, 1% methoxetamine, 0.5%
mephedrone, 0.5% Ayahuasca, 0.5% phenethylamines, 0%
kratom, and 0% desomorphine (Table 2).
4. Conclusions
To the best of our knowledge, this is the first paper providing
some data about NPS misuse in psychiatric patients; never-
theless, it is well known that psychiatric patients are much
more likely to have a substance or alcohol abuse problem than
general population [22–24].
Our results show a higher prevalence of habitual con-
sumption of alcohol and binge drinking behaviours in healthy
subjects in comparison with psychiatric patients. These data
may be explained with the widespread social use of alcohol
andwith the concept of the “drink in the company” as a social
glue, while it is known that psychiatric conditions lead to
marginalization and isolation. Another reasonmay be related
to the continuous contact of psychiatric patients withmedical
figures and drug therapies, which might contribute to a
reduction in the consumption of alcohol [25, 26].
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Table 2: Percentage use NPS.
Types of novel psychoactive substances Percentage use (%)
Healthy
subjects Patients
“Spices”
Synthetic cannabinoids 1% 5.8%
“Bath salts”
Mephedrone 0.3% 0.5%
“Ice-shaboo-crystal meth”
Methamphetamine 1.6% 3.4%
Ayahuasca 0.2% 0.5%
“Nbome-fly-solaris”
Phenethylamines 0.6% 0.5%
Salvia divinorum 1.1% 1%
Kratom 0.1% 0%
“Ghb”
Gamma hydroxybutyric acid 0.3% 1.9%
“Special m”
Methoxetamine 0.2% 1%
“Krokodil”
Desomorphine 0.2% 0%
On the other side, the consumption of NPS and cocaine
was significantly higher in the patients group than among
healthy subjects. These data may have different meanings:
firstly, there is the possibility that the use of these substances
is itself a factor able to trigger prodromal symptoms to full
development; on the other hand, subjects with psychiatric
disorder may be more motivated to try compounds con-
sidered harmful and/or illegal, possibly as self-medication
agents.These are of course only speculations not fully justified
by our data, but may represent future hypothesis that need to
be investigated. The presence of a quite high percentage of
patients with a diagnosis in the area of psychotic and bipolar
disorders associated with the use of cannabis is of clinical
interest. From our data it is not possible to understand if
cannabis use represents a predisposing factor. However, this
association gives further emphasis to the debated issue of a
relationship between cannabis and major psychiatric dis-
orders [3, 27, 28]. Other data on substances consumption
registered for different psychiatric diagnoses were suggestive
and worthy of interest despite being limited by the smallness
of the subgroups.
In our study, the use of NPS in healthy subjects and
psychiatric patients is statistically in favour of the patients
group (9.8% versus 3%; 푃 < 0.001). The situation of NPS
consumption in Europe, in response to recent developments
in EU drug market, is analysed by the Eurobarometer “Youth
attitudes on Drugs”.The survey asked adolescents and young
adults about their experiences and attitudes towards new psy-
choactive substances.The sample included over 12000 youths
aged 15–24, randomly selected across the 27 EU Member
States. Overall, 5% of the participants reported having used
NPS: Ireland (16%), Poland (9%), Latvia (8.8%) and United
Kingdom (8%) were way above the mean, while Italy (0.8%),
Finland (1%) and Greece (1.6%) were at the bottom of the
list [29]. On the other hand, our recent Italian data showed a
higher percentage ofNPS consumption in healthy subjects, as
well as a considerable higher percentage in psychiatric
patients. This could be due to selection biases, but it is also
possible that the extent of NPS consumption may be growing
or it was previously underestimated.
In our sample, we have evidenced a relevant of use of syn-
thetic cannabinoids among both patients (5.8%) and healthy
controls (1%). Being one of the most known and used NPS,
synthetic cannabinoids may represent a significant health
issue. Moreover, Spice use is apparently gaining popularity
among teenagers and young adults in the US, and a European
survey found similar figures, with a 7% prevalence of lifetime
use in a sample aged 15 to 18 years [30, 31]. The strong psy-
chotogenic action of synthetic cannabinoids is supposed to be
due to their higher affinity for cannabinoid receptors and
to their lower concentration of cannabidiol [32, 33]. Papanti
et al. recently coined the term “Spiceophrenia,” to define the
peculiar psychopathological characteristics of spice-induced
psychosis: according to their assumptions, it is possible to
hypothesize that the use of synthetic cannabinoids may “trig-
ger” the occurrence or the relapse of psychosis in psychosis-
vulnerable individuals or in patients with a prodromal psy-
chotic syndrome [34].
Cathinones derivatives, and especially mephedrone, have
become a particularly widespread phenomenon in the UK
in 2010, with a peak of 23.4% of Scottish students who had
used the substance at least once in their life [35, 36]. In our
sample, mephedrone was used by 0.3% of healthy subjects
and 0.5% of psychiatric patients. Mephedrone core activity is
mainly stimulant-like, with desired effects such as mood
enhancement and alertness, but may also determine the dev-
elopment of hallucinogenic symptoms, anxiety, agitation, and
confusion, with unpredictable consequences, especially in
nonhealthy users [37].
Our results indicated other potentially alarming trends
of misuse, such as phenethylamines and derivatives (0.6% in
healthy controls and 0.5% in patients), Salvia divinorum (1.1%
in healthy subjects and 1% in psychiatric sample), and even
pharmaceutical products (e.g., 0.3% of healthy sample and
1.9% of patients declared to have assumed GHB for recre-
ational purpose).
Clinicians could argue that NPS may reduce the efficacy
of the treatments for psychiatric disorders, worsen symptoms,
and reduce the adherence to therapeutic plans. On the other
hand, health and other professionals should be rapidly and
accurately informed about these new and serious trends of
misuse. A questionnaire administered to professionals from
the departments of addiction, psychiatry, and paediatrics
and emergency room in Italy has highlighted that intervie-
wees self-reported a poor technical knowledge of NPS. 27%
of the respondents confirmed not being aware if their patients
had a previous history of NPS misuse and most health
professionals appeared to have concerns relating to asso-
ciated medical and psychopathological risks, especially in
terms of aggression/psychomotor agitation. Overall, most
respondents reported the need to have better access to NPS-
related reliable sources of information [38].
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The use of NPS represents therefore a serious issue from
both a clinical and a public health point of view. For these
reasons, careful and constantmonitoring, accurate evaluation
of possible clinical effects related to their use, and develop-
ment of prevention measures are necessary to tackle the wide
escalation of NPS and to contribute in improving the quality
of public health on a global level.
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